Zydus Cadila gets US FDA nod to market skin-care ointment

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the exchanges in India on Wednesday, Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Cadila Group) said of having got approval from US FDA (Food & Drugs Administration) to market skin-care ointment.

Zydus Cadila has received the final approval from the USFDA to market Clobetasol Propionate Cream, (US RLD — Temovate® Cream), 0.05%, the release said.

Clobetasol Propionate is a topical (for the skin) steroid used to treat inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.

It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

The group now has 222 approvals and has so far filed over 330 ANDAs since thecommencement ofthe filing process in FY 2003-04.

Announcement from the company had hit the exchanges while trading session continued, somehow the announcement did not woo the investors & traders and the company shares ended in RED Zone on negative counters.